Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michael Mull

Physician Assistant Pittsburgh, PA Physician Assistant

NPI 1194225342 CMS profile 10678334

1400 Locust St Ste 5120, Pittsburgh, PA 15219

Open in the dashboard

General payments

$9,803

519 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Mull of Pittsburgh, PA is reported in the CMS Open Payments database as having received $9,803 across 519 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $539 9
2024 General $545 8
2023 General $506 9
2022 General $3,132 177
2021 General $5,081 316

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Mull
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Michael Mull were reported at $539. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Michael Mull Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $5,081 $132 $37–$438 $132
2022 $3,132 $155 $48–$522 $149
2023 $506 $167 $52–$557 $160
2024 $545 $178 $55–$600 $164
2025 $539 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,044 147 payments
  2. Sanofi-Aventis U.S. LLC $1,082 49 payments
  3. Lilly USA, LLC $1,069 56 payments
  4. AstraZeneca Pharmaceuticals LP $712 21 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $605 35 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $601 38 payments
  7. Amneal Pharmaceuticals LLC $528 26 payments
  8. Dexcom, Inc. $523 8 payments
  9. Amgen Inc. $379 13 payments
  10. AbbVie, Inc. $309 21 payments
  11. Other $1,951 105 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,759 517 payments
  2. Education $44 2 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,568 121 payments
  2. RYBELSUS $1,211 116 payments
  3. FARXIGA $669 19 payments
  4. JARDIANCE Diabetes $605 35 payments
  5. Kerendia $601 38 payments
  6. SOLIQUA 100/33 $569 28 payments
  7. UNITHROID $528 26 payments
  8. TRULICITY $404 26 payments
  9. JARDIANCE Diabetes $404 26 payments
  10. BAQSIMI $378 19 payments
  11. Other $5,305 243 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

2,552

Median for Physician Assistant: 241

Drug cost

$1,278,459

Median for Physician Assistant: $4,110

Branded share of claims

70.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 193 $235,607
Trulicity Dulaglutide Brand 179 $210,404
Mounjaro Tirzepatide Brand 143 $169,362
Jardiance Empagliflozin Brand 125 $143,707
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 59 $91,486
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 16 $54,731
Humalog Kwikpen U-100 Insulin Lispro Brand 106 $40,140
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 48 $38,628
Rybelsus Semaglutide Brand 20 $34,866
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 214 $33,403

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$13,046

Medicare's payments for the services billed

Medicare patients

118

Average age 67

Services billed

226

61 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 53%
Ischemic heart disease 46%
Arthritis 46%
Heart failure 35%
Depression 30%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $121
$121 — —
MOUNJARO
  • Lilly USA, LLC $114
$114 143 —
RYBELSUS
  • Novo Nordisk Inc $6
$6 20 —
Ozempic
  • Novo Nordisk Inc $6
$6 193 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

519 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record